Lates News

According to the AI flash news from Every Economy, Wanlian Securities released a research report on October 31, giving Wanhua Bio-Technology (603983.SH) a "buy" rating. The main reasons for the rating include: 1) product differentiation: revenue growth rates vary by product category, with increased average selling prices driving performance growth; 2) optimization of product structure to increase gross profit margins, but rapid increase in expenses leading to a flat year-on-year net profit margin. (Daily Economic News)